CRH PLC / Arcosa: Analyst & Investor Therapy + Feedback Post Arcosa (ACA) Deal

Research evidence excerpt

CRH PLC / Arcosa: Analyst & Investor Therapy + Feedback Post Arcosa (ACA) Deal

Equity Research

23 June 2026

CRH PLC / Arcosa

Analyst & Investor Therapy +

Feedback Post Arcosa (ACA) Deal

CRH’s ACA deal crystallizes value in a favorable backdrop, ACA OVERWEIGHT

POSITIVEsparking “too soon vs. full value” debate. ACA sheds U.S.ConstructionMachinery &

execution risk at ~15x while ceding synergy upside potential. Price Target USD 140.00

CRH gains a scaled ES platform with manageable transaction Price (22-Jun-26) USD 144.90 Potential Upside/Downside -3.4%

Source: Bloomberg, Barclays Researchrisk and cost improvement potential across materials, in our

view.

CRH OVERWEIGHT

U.S. Machinery & POSITIVE ConstructionCRH’s announced acquisition of Arcosa has driven a wide amount of takes and emotions

Price Target USD 131.00

amongst the investors and industry contacts we interact most with. Views have swayed

Price (22-Jun-26) USD 111.25

from full-value to too cheap; from ACA’s long-term strategic success to full monetization

Potential Upside/Downside +17.8%

too soon; from in CRH’s infrastructure wheelhouse to entirely outside of it. We recap it all Source: Bloomberg, Barclays Research

below with our own two-cents.

Arcosa had a unique story since separation that benefited from smart capital allocation U.S. Machinery & Construction

decisions and a bit of luck (IRA, AI, barge dynamics in the end). After divesting a number of Adam Seiden, CFA

businesses and investing in a few businesses, the path forward, realistically, remained dynamic +1 212 526 2212

adam.seiden@barclays.combut less in their control. Ultimately, the company was shifting from growth to execution mode.

BCI, US

By selling the business to CRH now, ACA offloads the execution risk and monetizes at a point